Platelet transfusion and alternatives to transfusion in patients with malignancy

Stem Cells
L VaickusK C Anderson

Abstract

Platelet transfusions have long had an important role in the treatment of patients with thrombocytopenia due to disease or myelotoxic treatment or in patients with reduced platelet function. However, platelet transfusions are associated with numerous risks, both immunologic (e.g., transfusion reactions, alloimmunization, immunosuppression) and infectious (e.g., viral, bacterial). In addition, several laboratory and clinical factors can influence post-transfusion platelet recovery. Recent technological advances have introduced the potential for using alternatives to platelet transfusions, such as cytokines or platelet substitutes, which may avoid the risks of transfusion. Platelet development from megakaryocytes is a process that is highly regulated by cytokines and animal research suggests that selected cytokines involved in this process may be useful in the treatment of thrombocytopenia. Newer developments, including the utilization of recombinant cytokines with relatively selective stimulation of platelet production (e.g., interleukin 6 [IL-6]) and the recent discovery of a megakaryocyte colony stimulating factor (thrombopoietin), represent major therapeutic opportunities in the treatment of thrombocytopenia. Platelet substit...Continue Reading

References

Jul 1, 1978·Transfusion·J E Howard, H A Perkins
Jan 1, 1992·Annals of Internal Medicine·M H SayersL E Silberstein
Aug 16, 1992·The New England Journal of Medicine·J G DonahueK E Nelson
Jan 1, 1991·The American Journal of the Medical Sciences·E P Frenkel
Sep 1, 1990·Transfusion·M E Brunson, J W Alexander
Jun 7, 1990·The New England Journal of Medicine·D M SurgenorR H Chapman
Jun 1, 1990·Transfusion·J H Hoofnagle
May 1, 1989·International Journal of Cell Cloning·T P McDonald
Sep 1, 1988·Transfusion·S Murphy
Sep 1, 1986·The American Journal of Medicine·K C AndersonB Sullivan
Jan 1, 1987·Transfusion·J M HealR L Stricof
Apr 3, 1987·JAMA : the Journal of the American Medical Association
Jul 27, 1972·The New England Journal of Medicine·L A Harker, S J Slichter
Jan 1, 1973·Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics·T OzawaS Su
Feb 3, 1966·The New England Journal of Medicine·F A Flatow, E J Freireich
Feb 1, 1980·JAMA : the Journal of the American Medical Association·P A DalyP H Wiernik
Jan 1, 1993·Veterinary Immunology and Immunopathology·Y NakajimaK Yasukawa
Jul 1, 1993·Stem Cells·C L Erickson-MillerM J Murphy
Jun 16, 1994·Nature·D Metcalf
Jul 1, 1993·Stem Cells·S Neben, K Turner
Mar 18, 1993·The New England Journal of Medicine·R A ShivdasaniK C Anderson

❮ Previous
Next ❯

Citations

Jun 7, 2006·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Rie TerasawaAtsushi Yoshizawa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.